LEIDEN, NETHERLANDS -- (MARKET WIRE) -- 12/19/2005 -- Leiden, The Netherlands, December 19, 2005 - Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL) announced today that it has signed a non-exclusive STAR™ research license agreement for the production of monoclonal antibodies with Cambridge, Massachusetts-based Genzyme Corporation. Financial details were not disclosed.
